Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment (2024)

Market Closed - Nyse Other stock markets 04:00:02 2024-05-24 pm EDT			5-day change	1st Jan Change
41.24 ^USD	-0.72%		-6.34%	-19.63%

May. 23	Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment	MT
May. 22	Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million	RE

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Bristol-Myers Squibb Company

Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment	May. 23	MT
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million	May. 22	RE
Bristol-Myers Squibb Announces Strategies to Improve Access to Medicines	May. 22	MT
Bristol Myers: 10-year strategy for poor countries	May. 22	CF
Bristol-Myers Squibb Invests in NeoPhore	May. 22	MT
Neophore Limited announced that it has received funding from a group of investors	May. 21	CI
Bristol Myers: national schizophrenia campaign	May. 21	CF
Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab	May. 21	MT
Bristol Myers: deadline set for subcutaneous Opdivo	May. 21	CF
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (Nivolumab and Hyaluronidase)	May. 21	CI
Everlasting momentum	May. 16
Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma	May. 16	DJ
Bristol-Myers Squibb Gets FDA Accelerated Approval for Breyanzi for Follicular Lymphoma	May. 16	MT
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma	May. 15	CI
US FDA approves expanded use of Bristol's cancer cell therapy	May. 15	RE
Transcript : Bristol-Myers Squibb Company Presents at Bank of America Health Care Conference 2024, May-15-2024 11:20 AM	May. 15
Transcript : Bristol-Myers Squibb Company Presents at Guggenheim Securities Radiopharmaceuticals Day, May-13-2024 11:00 AM	May. 13
Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint	May. 10	MT
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint	May. 10	DJ
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial	May. 10	CI
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says	May. 10	RE
Declaration of Voting Results by Bristol-Myers Squibb Company	May. 09	CI
Declaration of Voting Results by Bristol-Myers Squibb Company	May. 09	CI
India's Alembic Pharma posts higher Q4 profit on strong N.America sales	May. 09	RE
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	May. 07	MT

Chart Bristol-Myers Squibb Company

Duration

Period

More charts

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

2024-05-29 - American Society of Clinical Psychopharmacology Meeting - Poster Number: W86

Related indices

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology January 09, 2024 at 01:06 pm EST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.24USD

Average target price

53.19USD

Spread / Average Target

+28.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-19.63%	83.6B
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
	-6.23%	354B
	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals

Stock Market
Equities
BMY Stock
News Bristol-Myers Squibb Company
Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment

All transcripts on over 9000 companies, on the day they post their earnings! Unlock them now!

"); InvestingChannelQueue.push(function() { aICTags["oop"] = ic_page.defineOutOfPageTag("4Traders/quotepages","zppOOP"); aICTags["oop"].setKval({"adslot":"d_OOP_1"}); aICTags["oop"].render(); }); while (aAdsQueue.length) { (aAdsQueue.shift())(); } InvestingChannelQueue.push(function() { displayViewableAds('InvestingChannel'); $( window ).scroll(function() { displayViewableAds('InvestingChannel'); }); }); }gaEvent('adspv', 'InvestingChannel', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '11877');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });